Arcus Biosciences, Inc. (RCUS) NYSE

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Terry J. Rosen	Co-Founder, Chairman & Chief Executive Officer	1.45M	1960
Carolyn C. Tang	General Counsel & Corporate Secretary	603,200	1979
Robert C. Goeltz	Principal Financial Officer & Chief Financial Officer	792,694	1973
Richard A. Markus	Chief Medical Officer	933,883	N/A
Jennifer A. Jarrett	Advisor	1M	1971
Juan Carlos Jaen	Co- Founder & President	1.01M	1958
Holli Kolkey	Vice President of Corporate Communications	0	N/A
Alexander Azoy	Chief Accounting Officer	0	1976
Pia Eaves	Vice President of Investor Relations & Strategy	0	N/A
K. Christopher Garcia	Co-Founder & Member of Scientific Advisory Board	0	N/A
Jonathan Yingling	Chief Scientific Officer	0	1969

Name

Title

Pay

Year Born

Terry J. Rosen

Co-Founder, Chairman & Chief Executive Officer

1.45M

1960

Carolyn C. Tang

General Counsel & Corporate Secretary

603,200

1979

Robert C. Goeltz

Principal Financial Officer & Chief Financial Officer

792,694

1973

Richard A. Markus

Chief Medical Officer

933,883

N/A

Jennifer A. Jarrett

Advisor

1971

Juan Carlos Jaen

Co- Founder & President

1.01M

1958

Holli Kolkey

Vice President of Corporate Communications

N/A

Alexander Azoy

Chief Accounting Officer

1976

Pia Eaves

Vice President of Investor Relations & Strategy

N/A

K. Christopher Garcia

Co-Founder & Member of Scientific Advisory Board

N/A

Jonathan Yingling

Chief Scientific Officer

1969

Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.